CHICAGO—Findings from an expanded phase I study in 107 patients with metastatic melanoma suggest that PD-1 inhibition with the novel agent nivolumab could bring extended remissions. Sarah Maxwell heard the latest at the American Society of Clinical Oncology’s 2013 meeting in Chicago from Dr. Mario Sznol MD, Clinical Research Program Leader at Yale Cancer Center, New Haven, CT and Dr. Lynn Schuchter Chief of Hematolgy/Oncology at the Abramson Cancer Center, University of Pennsylvania, Philadelphia.
You may also like...
Ultrahypofractionated Radiation Just As Effective for Prostate Cancer 16 May, 2018 Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue! 6 Oct, 2009 Audio Journal of Oncology in Advance – May 15th, 2007 – reporting from: American Association for Cancer Research, April 14-18, 2007, Los Angeles, CA 16 May, 2007 ASCO Annual Meeting Daily News Podcasts – June 5th, 2007 5 Jun, 2007
- Previous story Combination immunotherapy improved overall survival in patients with metastatic melanoma
- Next story Novel oral anticoagulants: latest opinion from the ESC congress
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014